Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients (PAD)
Recruitment status was Not yet recruiting
Patients with kidney failure on dialysis can be successfully transplanted. However, many of them do not attain a normal kidney function and/or present a slow deterioration of kidney function after transplantation. As a consequence, they can develop an endocrine disorder called hyperparathyroidism, which can cause bone disease and a high risk of bone fractures. In spite of the known bone disease and hyperparathyroidism, there is no well defined treatment for these patients.
Moreover, kidney transplant recipients present a higher mortality rate compared to the general population, and the principal cause of death is cardiovascular disease. Dialysis patients are known to have extensive cardiovascular calcifications and increased vascular stiffness, and these factors have been closely associated with cardiovascular mortality.
The effect of vitamin D on bone health is well known in the general population. Many studies showed a reduction in fracture rate in post-menopausal women and older men receiving vitamin D and calcium supplements. Vitamin D analogues are also commonly used to treat hyperparathyroidism in dialysis patients. Finally, vitamin D has been suggested to have beneficial effects on the cardiovascular system and to reduce mortality in dialysis patients.
Hectorol® is a vitamin D analog which has been demonstrated to effectively treat hyperparathyroidism in dialysis and pre-dialysis patients.
The effects of vitamin D supplementation on bone disease, hyperparathyroidism and cardiovascular function in kidney transplant recipients have not been properly studied.
Whether Hectorol® therapy helps reducing the severity of bone disease and improving vascular function in kidney transplant recipients is still unknown.
We plan to study the cardiovascular and bone effects of Hectorol® in 100 kidney transplant recipients followed at our Transplant Clinic. We will screen kidney transplant patients for kidney transplant dysfunction and hyperparathyroidism. The study medication will be given to 50 patients. The other 50 patients will continue to be treated with the actual standard of care at our Transplant Clinic. We will follow these patients for 18 months and monitor laboratory values, bone density, vascular calcification and stiffness to detect any effect of Hectorol® compared to the actual standard of care.
Other: standard of care
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney|
- iPTH serum levels [ Time Frame: 18 months ] [ Designated as safety issue: No ]
- bone mineral density, vascular calcification, vascular stiffness, endothelial function, estimated glomerular filtration rate, proteinuria, rejection rate [ Time Frame: 18 months ] [ Designated as safety issue: No ]
|Study Start Date:||April 2008|
|Estimated Study Completion Date:||June 2010|
|Estimated Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Active Comparator: 1
The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
Other Name: Hectorol
Standard of care
Other: standard of care
No study drug
Other Name: No intervention
Please refer to this study by its ClinicalTrials.gov identifier: NCT00646282
|Contact: Paolo Raggi, MDfirstname.lastname@example.org|
|Contact: Antonio Guasch, MDemail@example.com|
|United States, Georgia|
|Emory University||Not yet recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: Paolo Raggi, MD 404-778-5414 firstname.lastname@example.org|
|Contact: Antonio Guasch, MD 404-727-3959 email@example.com|
|Sub-Investigator: Francesca Cardarelli, MD|
|Principal Investigator:||Paolo Raggi and Antonio Guasch, MDs||Emory University|